These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31399784)

  • 1. Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs.
    Calvani N; Morelli F; Naglieri E; Gnoni A; Chiuri VE; Orlando L; Fedele P; Cinieri S
    Med Oncol; 2019 Aug; 36(9):80. PubMed ID: 31399784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
    Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
    Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
    Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
    Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metronomic chemotherapy with oral cyclophosphamide : An individual option for the metastatic castration-resistant prostate cancer patient?].
    Knipper S; Mandel P; V Amsberg G; Strölin P; Graefen M; Steuber T
    Urologe A; 2019 Apr; 58(4):410-417. PubMed ID: 29808369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
    Jeong Y; Lee JL
    Asia Pac J Clin Oncol; 2017 Jun; 13(3):204-211. PubMed ID: 27521286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
    Barroso-Sousa R; da Fonseca LG; Souza KT; Chaves AC; Kann AG; de Castro G; Dzik C
    Med Oncol; 2015 Jan; 32(1):443. PubMed ID: 25519824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center.
    Dabkara D; Ganguly S; Biswas B; Ghosh J
    Indian J Cancer; 2018; 55(1):94-97. PubMed ID: 30147102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
    Podrazil M; Horvath R; Becht E; Rozkova D; Bilkova P; Sochorova K; Hromadkova H; Kayserova J; Vavrova K; Lastovicka J; Vrabcova P; Kubackova K; Gasova Z; Jarolim L; Babjuk M; Spisek R; Bartunkova J; Fucikova J
    Oncotarget; 2015 Jul; 6(20):18192-205. PubMed ID: 26078335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
    Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
    BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
    Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
    Puente J; González-Del-Alba A; Sala-Gonzalez N; Méndez-Vidal MJ; Pinto A; Rodríguez Á; Cuevas Sanz JM; Muñoz Del Toro JR; Useros Rodríguez E; García García-Porrero Á; Vázquez S
    BMC Cancer; 2019 Aug; 19(1):766. PubMed ID: 31382926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
    Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS
    Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.
    Lo EN; Beckett LA; Pan CX; Robles D; Suga JM; Sands JM; Lara PN
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):144-8. PubMed ID: 25667107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
    Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
    BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.